Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.
There is an urgent need for an improved vaccine against tuberculosis. Heterologous prime-boost immunization regimes induce higher levels of cellular immunity than homologous boosting with the same vaccine. Using BCG as the priming immunization in such a regime allows for the retention of the benefic...
Príomhchruthaitheoirí: | Mcshane, H, Pathan, A, Sander, C, Goonetilleke, N, Fletcher, H, Hill, A |
---|---|
Formáid: | Journal article |
Teanga: | English |
Foilsithe / Cruthaithe: |
2005
|
Míreanna comhchosúla
Míreanna comhchosúla
-
Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
de réir: Whelan, K, et al.
Foilsithe / Cruthaithe: (2009) -
Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1.
de réir: Fletcher, H, et al.
Foilsithe / Cruthaithe: (2008) -
Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
de réir: Kathryn T. Whelan, et al.
Foilsithe / Cruthaithe: (2011-01-01) -
Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
de réir: Pathan, A, et al.
Foilsithe / Cruthaithe: (2012) -
Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
de réir: Pathan, A, et al.
Foilsithe / Cruthaithe: (2012)